Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3

Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3 PR Newswire

* Successfully listed on the Nasdaq Capital Market under the ticker symbol LABT, marking a significant milestone in the Company's evolution * Strengthened balance sheet through completion of a $7.5 million private placement to support continued clinical advancement * Reported positive preclinical safety and tolerability data supporting dose selection for the upcoming Phase 2a clinical trial evaluating Nu-3 Gel in infected diabetic foot ulcers (iDFUs) * Announced internationally recognized diabetic foot expert David G. Armstrong, DPM, MD, Ph.D., as Study Chair and Scientific Advisor for the Phase 2a clinical program * Expanded global intellectual property portfolio with a new Australian composition-of-matter patent, bringing the Company's IP portfolio to 72 granted patents and 29 pending patents * Continued to demonstrate Nu-3's differentiated antimicrobial profile, including rapid broad-spectrum activity against multidrug-resistant pathogens without generating resistance in comparative preclinical studies SARASOTA, Fla., Sept. 21, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc. , (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin(®) class, today announced that Kelvin Cooper, Ph.D., Chief Executive Officer of Lakewood-Amedex Biotherapeutics, has issued a Letter to Shareholders highlighting the Company's recent clinical, corporate and financial achievements and outlook as it advances Nu-3 into Phase 2 clinical development. The full text of the letter follows.